GURUFOCUS.COM » STOCK LIST » USA » NYSE » Perrigo Co PLC (NYSE:PRGO) » Definitions » EV-to-EBIT
Switch to:

Perrigo Co EV-to-EBIT

: 20.36 (As of Today)
View and export this data going back to 1991. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Perrigo Co's Enterprise Value is $7,279 Mil. Perrigo Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2022 was $358 Mil. Therefore, Perrigo Co's EV-to-EBIT for today is 20.36.

The historical rank and industry rank for Perrigo Co's EV-to-EBIT or its related term are showing as below:

PRGO' s EV-to-EBIT Range Over the Past 10 Years
Min: -127.35   Med: 25.25   Max: 96.48
Current: 19.97

During the past 13 years, the highest EV-to-EBIT of Perrigo Co was 96.48. The lowest was -127.35. And the median was 25.25.

PRGO's EV-to-EBIT is ranked worse than
61.19% of 675 companies
in the Drug Manufacturers industry
Industry Median: 16.06 vs PRGO: 19.97

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Perrigo Co's Enterprise Value for the quarter that ended in Mar. 2022 was $6,722 Mil. Perrigo Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2022 was $358 Mil. Perrigo Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2022 was 5.32%.


Perrigo Co EV-to-EBIT Historical Data

The historical data trend for Perrigo Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Perrigo Co Annual Data
Trend Jun12 Jun13 Jun14 Jun15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EV-to-EBIT
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.13 18.96 37.84 67.71 18.33

Perrigo Co Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
EV-to-EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 88.10 -121.93 29.85 18.33 18.80

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Perrigo Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Perrigo Co EV-to-EBIT Distribution

For the Drug Manufacturers industry and Healthcare sector, Perrigo Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Perrigo Co's EV-to-EBIT falls into.



Perrigo Co EV-to-EBIT Calculation

Perrigo Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=7278.910/357.5
=20.36

Perrigo Co's current Enterprise Value is $7,279 Mil.
Perrigo Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $358 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Perrigo Co  (NYSE:PRGO) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Perrigo Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2022 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2022 ) =EBIT / Enterprise Value (Q: Mar. 2022 )
=357.5/6722.378
=5.32 %

Perrigo Co's Enterprise Value for the quarter that ended in Mar. 2022 was $6,722 Mil.
Perrigo Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $358 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Perrigo Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Perrigo Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Perrigo Co Business Description

Perrigo Co logo
Address
The Sharp Building, Hogan Place, Dublin, IRL, D02 TY74
Perrigo Co PLC is a leading private label supplier of generic over the counter (OTC) drugs in the U.S. and Europe. The company's product offerings fall under traditional OTC drug categories (i.e. cough, cold, allergy, pain), in addition to oral care, infant nutrition (formula), and nicotine cessation aids. In addition to private label manufacturing, the company also sells products under its own brands (largely in the skincare and oral-care category). The company became a pure-play in OTC consumer healthcare in 2021, following a series of divestitures over several years (sold off generic prescription topicals, animal health, and active pharmaceutical ingredient business). In late 2021, Perrigo signed an offer to acquire HRA Pharma.
Executives
Ives Alison officer: EVP & Chief Scientific Officer C/O PERRIGO COMPANY PLC 515 EASTERN AVENUE ALLEGAN MI 49010
Hanson Kyle officer: EVP & General Counsel
Bezerra Eduardo Guarita officer: EVP & Chief Financial Officer C/O FRESH DEL MONTE PRODUCE INC. PO BOX 149222 CORAL GABLES FL 33134
Ashford Orlando D director C/O AMERANT BANK 220 ALHAMBRA CR. CORAL GABLES FL 33134
Doyle Katherine C. director 100 ABBOTT PARK ROAD, AP6C-1N D032L ABBOTT PARK IL 60064
Sorota Richard S officer: EVP & President CSCA HARMAN INTERNATIONAL INDUSTRIES, INC. 1101 PENNSYLVANIA AVE, NW, #1010 WASHINGTON DC 20004
Mann Erica L director ONE KELLOGG SQUARE P.O. BOX 3599 BATTLE CREEK MI 49016-3599
Silcock Raymond officer: EVP, Chief Financial Officer 399 JEFFERSON ROAD PARSIPPANY NJ 07054
Willis Robert officer: Acting CHRO C/O PERRIGO COMPANY PLC 515 EASTERN AVENUE ALLEGAN MI 49010
Dillard James E Iii officer: EVP, Chief Scientific Officer 6601 WEST BROAD STREET RICHMOND VA 23230
Kessler Murray S director, officer: CEO 714 GREEN VALLEY ROAD GREENSBORO NC 27408
Smith Jeffrey C director 777 THIRD AVENUE, 18TH FLOOR NEW YORK NY 10017
Roehrhoff Uwe director, officer: CEO C/O PERRIGO COMPANY PLC TREASURY BUILDING, LOWER GRAND CANAL ST DUBLIN L2 D2
Classon Rolf A director C/O CATALENT, INC. 14 SCHOOLHOUSE ROAD SOMERSET NJ 08873
Karaboutis Adriana director C/O BIOGEN IDEC INC. 225 BINNEY ST. CAMBRIDGE MA 02142

Perrigo Co Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)